AUS
NZ
UK
CA
USA
IND
-Copy_08_27_2024_15_08_59_207354.jpg)
Diaceutics (LSE:DXRX) announced a major enhancement to its rare-disease offerings on Tuesday, marked by the acquisition of a new contract designed to support the commercialization of a therapy for rare diseases.
The AIM-listed company revealed that the expansion is set to transform the early identification of patients, a crucial aspect for pharmaceutical companies developing treatments for rare conditions.
A key component of this enhancement is the broadened lab network, which now features several new genomic lab data partners specializing in rare diseases. Notably, the addition of the largest genetic testing lab in the US is expected to provide essential data for improving early patient diagnosis.
The expanded network is anticipated to be instrumental in identifying rare disease patients at earlier stages, thereby improving clinical outcomes and enhancing the likelihood of successful treatments.
Diaceutics also highlighted advancements in its lab labeling capabilities, achieved through the implementation of natural language processing (NLP) technology. This upgraded NLP process enables more accurate and standardized data processing, addressing a longstanding challenge by differentiating between pathogenic variants and variants of unknown significance (VUS).
The company noted that these technological improvements are projected to significantly enhance the value of the data utilized by pharmaceutical companies in diagnosing and treating rare diseases.
Additionally, Diaceutics has strengthened its team by incorporating industry experts with extensive experience in rare diseases. This expanded expertise is intended to assist biopharma clients in maximizing the benefits of Diaceutics' advanced data capabilities and meeting the complex needs of this specialized market.
The recent strategic enhancements have already led to a successful contract win, providing a multi-product solution to support the commercialization of a therapy for a rare autosomal-recessive disease.
Chief Data Officer Jordan Clark commented, “These enhancements to our rare-disease data offering represent significant progress in our mission to support the earlier identification and treatment of patients with rare diseases. By integrating new data, advanced labeling, and a specialized team, we are well-positioned to address the critical needs of this underserved market and aid patients in need.”
At 1110 BST, shares in Diaceutics increased by 2.69% to 133.5p
